While demonstrating notable efficacy in these studies, in general, systemic BCL-2 inhibition caused lymphopenia, neutropenia, and thrombocytopenia, which required Venetoclax discontinuation in a substantial proportion of patients [51]. This evidence concerns the gene BCL2 and Decreased total neutrophil count.